for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Eli Lilly Receives FDA Breakthrough Therapy Designation For Baricitinib For The Treatment Of Alopecia Areata

March 16 (Reuters) - Incyte Corp, Eli Lilly :

* LILLY RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR BARICITINIB FOR THE TREATMENT OF ALOPECIA AREATA

* ELI LILLY AND COMPANY- FDA HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO BARICITINIB FOR TREATMENT OF ALOPECIA AREATA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up